|1.||Moridani, Majid Y: 2 articles (11/2006 - 01/2003)|
|2.||Masotti, A: 1 article (03/2010)|
|3.||Di Nuzzo, S: 1 article (03/2010)|
|4.||Keeling, Jon: 1 article (02/2008)|
|5.||Epstein, Rachel: 1 article (02/2008)|
|6.||Benitez, Adolpho: 1 article (02/2008)|
|7.||Rendon, Marta: 1 article (02/2008)|
|8.||Cardona, Lina: 1 article (02/2008)|
|9.||Ortonne, Jean-Paul: 1 article (09/2006)|
|10.||Cheon, Sophia S: 1 article (01/2003)|
01/01/1982 - "[Confetti depigmentation following application of Leucodinine B on a chloasma]."
02/01/2008 - "Mequinol 2%/tretinoin 0.01% topical solution was an effective and well-tolerated treatment of melasma in men. "
02/01/2008 - "This is the first report describing the use of mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men; there are no reports in women."
02/01/2008 - "We performed a case series assessing the use of mequinol 2%/ tretinoin 0.01% topical solution in 5 men with melasma. "
02/01/2008 - "Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: a case series and review of the literature."
|2.||Melanoma (Melanoma, Malignant)
11/18/2006 - "In the current work we investigated for the first time the biochemical basis of 4-hydroxyanisole (4-HA) induced toxicity in B16-F0 melanoma cells. "
11/18/2006 - "Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B16-F0 melanoma cells."
04/01/1992 - "Ten female patients with recurrent cutaneous malignant melanoma (MM) confined to the lower limb were treated with 4-hydroxyanisole (4HA) infused intra-arterially. "
01/01/1992 - "4-Hydroxyanisole is a depigmenting agent which has been shown to have activity against malignant melanoma when given intra-arterially in man. "
12/01/1990 - "The pharmacokinetic behaviour of 4-hydroxyanisole (4HA) has been studied in ten female patients with recurrent malignant melanoma confined to the lower limb. "
|3.||Hepatocellular Carcinoma (Hepatoma)
11/01/1981 - "Two men reported previously with vitiligo after occupational exposure to hydroquinone monomethyl ether (HMME) have been reviewed after eight years. "
03/01/2010 - "Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole."
05/01/2000 - "Our purpose was to evaluate the long-term effectiveness and safety of a combination therapy consisting of topical 4-methoxyphenol (4-MP) cream and Q-switched ruby (QSR) laser in 16 patients with vitiligo universalis. "
05/01/2000 - "Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser."
11/01/1981 - "Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol."
07/01/1977 - "The drug p-hydroxyanisole (OHA) was found to inhibit the incorporation of 3H-thymidine in the Harding-Passey melanoma cells in culture. "
01/01/1990 - "22.214.171.124) in the cytotoxicity of 4-hydroxyanisole (4HA) in vivo, we have compared the therapeutic effects of 4HA on the B16 melanoma and Harding-Passey melanoma, which differ significantly in their tyrosinase content. "
12/01/1988 - "Cytotoxicity of 4-hydroxyanisole and tyrosinase activity in variant cell lines of B16 melanoma."
|1.||Tretinoin (Retinoic Acid)
|3.||Monophenol Monooxygenase (Tyrosinase)
|5.||Phenol (Carbolic Acid)
|2.||Cryotherapy (Therapy, Cold)
|4.||Drug Therapy (Chemotherapy)